论文部分内容阅读
Objective:This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia(CLL)and a 17p deletion(17p-)and identify the predictive factors within this subgroup.Methods:The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22,13q14 and 17p13;trisomy of bands 12q13;and translocation involving band 14q32.The data from 456 patients with or without a 17p-were retrospectively collected and analyzed.Results:The overall response rate(ORR)in patients with a 17p-was 56.9%,and patients with a high percentage of 17p-(defined as more than 25%of cells harbouring a 17p-)had a lower ORR.The median overall survival(OS)in patients with a 17p-was 78.0 months,which was significantly shorter than the OS in patients without this genetic abnormality(median 162.0 months,P<0.001).Within the subgroup with a 17p-,the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase(LDH),B symptoms,unmutated IGHV and a high percentage of 17p-.Conclusions:These results indicated that patients with a 17p-CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup. Methods: The sample of patients with CLL were analyzed by fluorescence in situ Hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p-were retrospectively collected and analyzed. Results: The overall response rate (ORR) in patients with a 17p-was 56.9%, and patients with a high percentage of 17p- (defined as more than 25% of cells harbored a 17p-) had a lower ORR. median median survival (OS) in patients with a 17p- was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P <0.001) .Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage BC and patients with e Levated lactate dehydrogenase (LDH), B symptoms, unmutated IGHV and a high percentage of 17p-.Conclusions: These results indicated that patients with a 17p-CLL have a variable prognosis that might be predicted who used simple clinical and laboratory characteristics.